What are the trends of centralized drug procurement in 2020?

[pharmaceutical network market analysis] for the pharmaceutical industry, 2020 will undoubtedly be a year of great influence on the national drug bidding and procurement According to the road map of "one small step in a year, one big step in three years", if the establishment of Medical Security Bureau in 2018 is the year of institution setting, then 2019 is the year of resource allocation of drug centralized purchase, and 2020 is the year when drug centralized purchase really starts to work Therefore, the author specially combines the relevant policies and the current situation of drug bidding procurement in each province, combs the five characteristics of the national drug bidding procurement trend in 2020, and shares with you Price reduction is still the target of purchasing with quantity In fact, the centralized purchasing of drugs organized by the state is a major reform of the previous drug purchasing system, which aims to let the people use higher quality drugs at a relatively low price In the past, from the government led centralized bidding procurement system to the "4 + 7 bidding procurement mode" joint procurement, reducing drug prices has always been an important goal In 2020, according to the national unified deployment, the scope of centralized procurement and use of drugs by national organizations will continue to expand, that is, to increase the scope of varieties In the future, or not limited to 25 varieties, there may be more varieties selected for volume procurement, so that there will be more operable space for drug prices "National joint mining" may come Some insiders say that the "4 + 7" phase mission has been completed, and may enter a new phase of "national joint mining" in the future At present, it seems that through pilot and expansion, the conditions for nationwide combined mining are mature In 2019, the National Health Insurance Bureau launched the work of drug classification and coding, which will take three years to establish a new health insurance information system The national drug management platform is also under construction In the future, a higher platform may undertake more national centralized procurement work (such as negotiation, purchase with volume, etc.) Over evaluation and original research varieties will be "accurately hit" from "4 + 7" in 2018 to the expansion of joint mining in 2019, and the introduction of volume purchase policy has brought many very big changes to the pharmaceutical market It is not difficult to see through the two national joint mining that the country tries to achieve the obvious point to area effect through accurate strike and shows a continuous trend Therefore, for pharmaceutical enterprises, in 2020, in terms of variety selection and layout, we should shift from the previous large and wide to the refined and detailed, focus on key varieties, and strive to be both excellent and good in terms of cost of raw materials and other aspects, as well as quality management of pharmacovigilance system Great changes will take place in the generic drug market At present, more than 4700 pharmaceutical factories in China are basically engaged in the research and development of generic drugs, a small part of which is the combination of generic drugs and new drugs According to the current ranking of enterprises with product reviews and the selection of "4 + 7", the future generic pharmaceutical market will still be a contest of enterprise strength Giant generic pharmaceutical enterprises may appear under the influence of the dual policies of consistency evaluation and volume procurement, and the new pattern of generic pharmaceutical market will gradually form in the evolution of policy Recently, the community health service center in Guancheng street of Dongguan City issued the first "4 + 7" drug prescription, marking the implementation of the policy With the continuous expansion of volume procurement in China, and the current situation of the second batch of volume procurement, it is no doubt that the policy of the same price in the same city will be implemented in the grass-roots and retail markets in the future, which is very likely to re-establish the evaluation of drug procurement, affect the sales system of drug distribution and subcontracting, and reshape the new order of market pattern Conclusion: on the whole, the future of the pharmaceutical industry is very good, but today it is still very bony In the future, with the joint purchase of evaluated varieties, centralized purchase at the provincial level, group purchase, and further development of drug supply side increment and stock management, it will be more and more difficult for enterprises to maintain prices But only by sticking to it first can pharmaceutical companies have a chance to rush to the end and win.